Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$0.73 - $2.47 $8,418 - $28,484
11,532 Added 69.59%
28,104 $26,000
Q3 2021

Nov 15, 2021

BUY
$3.55 - $7.49 $58,830 - $124,124
16,572 New
16,572 $61,000

Others Institutions Holding ARDS

About Aridis Pharmaceuticals, Inc.


  • Ticker ARDS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,701,600
  • Description
  • Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...
More about ARDS
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.